Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

This study’s outcomes could significantly impact Regeneron and Sanofi’s stock performance, as positive results may enhance investor confidence and market position in the COPD treatment landscape. The ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

Sanofi’s investigational multiple myeloma (MM) therapy has been granted orphan drug designation by the US Food and Drug Administration (FDA) to treat patients with relapsed or refractory disease.

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

[PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology to streamline their development. The French drugmaker will pay US$1.15 ...

Sanofi gained its AI platform Pharma.AI in the process. That partnership followed Sanofi’s other AI collaborations, including deals with Exscientia and Owkin. Alex Zhavoronkov, CEO and founder at ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why SNY stock is a strong buy.

Sanofi’s pair of differentiated flu vaccines have demonstrated superiority over a standard-dose vaccine in control trials in older adults, Greenberg said. Fluad doesn't yet boast comparable data.

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

Sanofi's Tzield is now the first and only disease-modifying therapy to be approved for type 1 diabetes (T1D) in the UK.

Sanofi (ENXTPA:SAN) has made a move that is bound to get investors talking, as shares edged up just over 5% in the past week. While there is no headline-making event at play, this uptick arrives after ...